As such, the study, which is evaluating different pelareorep combination regimens in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers, has been recommended to continue as planned. The safety run-in for the third-line metastatic colorectal cancer (CRC) cohort is ongoing. Read more . . .
The 3-patient safety run-in for the pancreatic cancer cohort of the ongoing phase 1/2 GOBLET study did not reveal any safety concerns with the novel combination of pelareorep and atezolizumab (Tecentriq).1